Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Daratumumab for Childhood Nephrotic Syndrome
NCT05704400Phase 2Unknown
- Sponsor
- Istituto Giannina Gaslini
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in nephrotic syndrome, sponsored by Istituto Giannina Gaslini. Status: unknown.
02
Drugs
daratumumab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05704400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704400.